ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation

Journal of Cellular Biochemistry

Volumn 115, Issue 3, 2014, Pages 498-509

  Qie, Shuo ^a,b   Chu, Clarissa ^a   Li, Weihua ^c   Wang, Chenguang ^c   Sang, Nianli ^a,b,d  

^a DREXEL UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

BREAST CANCER; ErbB2; GLS1; GLUTAMINASE; GLUTAMINE; NUCLEAR FACTOR B

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTAMINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; BREAST CANCER; CANCER CELL; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STIMULATION; TUMOR CELL LINE; UPREGULATION;

BREAST CANCER; ERBB2; GLS1; GLUTAMINASE; GLUTAMINE; NUCLEAR FACTOR Κ B;

APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINASE; HUMANS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84892717735     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24684     Document Type: Article

References (54)

1. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN,. 1997. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci USA 94: 3627-3632.
2. Aledo JC, Gomez-Fabre PM, Olalla L, Marquez J,. 2000. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome 11: 1107-1110.
3. Baselga J, Swain SM,. 2009. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
4. Borrello MG, Degl'Innocenti D, Pierotti MA,. 2008. Inflammation and cancer: The oncogene-driven connection. Cancer Lett 267: 262-270.
5. Chodosh LA,. 2011. Breast cancer: Current state and future promise. Breast Cancer Res 13: 113.
6. Conant K, Atwood WJ, Traub R, Tornatore C, Major EO,. 1994. An increase in p50/p65 NF-κB binding to the HIV-1 LTR is not sufficient to increase viral expression in the primary human astrocyte. Virology 205: 586-590.
7. Cooney DA, Jayaram HN, Milman HA, Homan ER, Pittillo R, Geran RI, Ryan J, Rosenbluth RJ,. 1976. DON, CONV and DONV-III. Pharmacologic and toxicologic studies. Biochem Pharmacol 25: 1859-1870.
8. Dang CV,. 2010. Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells ? Cell Cycle 9: 3884-3886.
9. Dang CV, Hamaker M, Sun P, Le A, Gao P,. 2011. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 89: 205-212.
10. de la Rosa V, Campos-Sandoval JA, Martin-Rufian M, Cardona C, Mates JM, Segura JA, Alonso FJ, Marquez J,. 2009. A novel glutaminase isoform in mammalian tissues. Neurochem Int 55: 76-84.
11. DeBerardinis RJ, Cheng T,. 2010. Q's next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29: 313-324.
12. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB,. 2008. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18: 54-61.
13. Dizdar O, Altundag K,. 2009. Emerging drugs in metastatic breast cancer. Expert Opin Emerg Drugs 14: 85-98.
14. Erickson JW, Cerione RA,. 2010. Glutaminase: a hot spot for regulation of cancer cell metabolism ? Oncotarget 1: 734-740.
15. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES,. 2010. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 9: 4153-4163.
16. Galang CK, Garcia-Ramirez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, Oshima RG, Hauser CA,. 1996. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. J Biol Chem 271: 7992-7998.
17. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV,. 2009. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
18. Goldenberg MM,. 1999. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21: 309-318.
19. Gomez-Fabre PM, Aledo JC, Del Castillo-Olivares A, Alonso FJ, Nunez De Castro I, Campos JA, Marquez J, 2000. Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochem J 345 (Pt 2): 365-375.
20. Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P,. 2010. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 36 (Suppl 3): S62-S66.
21. Hynes NE, Lane HA,. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
22. Hynes NE, MacDonald G,. 2009. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
23. Jin HC, Liu X, Wang X, Zhang J, Lam EKY, Shin VY, Cheng ASL, Yu J, Chan FKL, Sung JJY,. 2010. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 29: 442-450.
24. Kawauchi K, Araki K, Tobiume K, Tanaka N,. 2008. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10: 611-618.
25. Kita K, Suzuki T, Ochi T,. 2007. Down-regulation of glutaminase C in human hepatocarcinoma cell by diphenylarsinic acid, a degradation product of chemical warfare agents. Toxicol Appl Pharmacol 220: 262-270.
26. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW, Dang CV, 2012. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15: 110-121.
27. Lebedeva ZI, Kabanova EA, Berezov TT,. 1986. 6-Diazo-5-oxo-L-norleucine and azaserine as affinity inhibitors of glutamin(asparagin)ase. Biochem Int 12: 413-420.
28. Levine AJ, Puzio-Kuter AM,. 2010. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340-1344.
29. Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, Zhong Z, McCue PA, Sang N, Ji JY, Kong B, Jiang J, Wang C,. 2012. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle 11: 2348-2358.
30. Liu M, Ju X, Willmarth NE, Casimiro MC, Ojeifo J, Sakamaki T, Katiyar S, Jiao X, Popov VM, Yu Z, Wu K, Joyce D, Wang C, Pestell RG,. 2009. Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol 174: 1910-1920.
31. Meng M, Chen S, Lao T, Liang D, Sang N,. 2010. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle 9: 3921-3932.
32. Merkhofer EC, Cogswell P, Baldwin AS,. 2010. Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 29: 1238-1248.
33. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE,. 2000. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19: 1647-1656.
34. Olayioye MA, Neve RM, Lane HA, Hynes NE,. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167.
35. Paris L, Cecchetti S, Spadaro F, Abalsamo L, Lugini L, Pisanu ME, Iorio E, Natali PG, Ramoni C, Podo F,. 2010. Inhibition of phosphatidylcholine- specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res 12: R27.
36. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE,. 2001. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20: 1287-1299.
37. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME,. 1997. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272: 21096-21103.
38. Qie S, Liang D, Yin C, Gu W, Meng M, Wang C, Sang N,. 2012. Glutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming. Cell Cycle 11: 3679-3690.
39. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band V, Band H,. 2008. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 7: 1630-1640.
40. Rana A, Rangasamy V, Mishra R,. 2010. How estrogen fuels breast cancer. Future Oncol 6: 1369-1371.
41. Rathore MG, Saumet A, Rossi JF, de Bettignies C, Tempe D, Lecellier CH, Villalba M,. 2012. The NF-kappaB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol 44: 1448-1456.
42. Reitzer LJ, Wice BM, Kennell D,. 1979. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254: 2669-2676.
43. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, Hansen JC, Curthoys NP,. 2007. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 406: 407-414.
44. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J,. 2003. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278: 14013-14019.
45. Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT,. 2011. Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl) 89: 229-236.
46. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
47. Srivastava SK, Ramana KV,. 2009. Focus on molecules: nuclear factor-kappaB. Exp Eye Res 88: 2-3.
48. Thompson CB, Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB,. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-18787.
49. Turowski GA, Rashid Z, Hong F, Madri JA, Basson MD,. 1994. Glutamine modulates phenotype and stimulates proliferation in human colon cancer cell lines. Cancer Res 54: 5974-5980.
50. Vander Heiden MG, Cantley LC, Thompson CB, 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
51. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, Cerione RA,. 2010. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18: 207-219.
52. Yarden Y, Sliwkowski MX,. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
53. Yin C, Qie S, Sang N,. 2012. Carbon source metabolism and its regulation in cancer cells. Crit Rev Eukaryot Gene Expr 22: 17-35.
54. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y,. 2007. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178: 93-105.